164 related articles for article (PubMed ID: 33588739)
1. STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany.
Lehner LJ; Kalb K; Weigand K; Pein U; Schenker P; Seeger W; Roehle R; Dienes K; Halleck F; Budde K
Curr Rev Clin Exp Pharmacol; 2021; 16(4):357-368. PubMed ID: 33588739
[TBL] [Abstract][Full Text] [Related]
2. Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients.
Naicker D; Reed PW; Ronaldson J; Kara T; Wong W; Prestidge C
Pediatr Nephrol; 2017 Nov; 32(11):2125-2131. PubMed ID: 28660366
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial.
Arns W; Huppertz A; Rath T; Ziefle S; Rump LC; Hansen A; Budde K; Lehner LJ; Shipkova M; Baeumer D; Kroeger I; Sieder C; Klein T; Schenker P
Transplantation; 2017 Nov; 101(11):2780-2788. PubMed ID: 28658202
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of clinical and safety outcomes associated with conversion from brand-name to generic tacrolimus in transplant recipients enrolled in an integrated health care system.
Spence MM; Nguyen LM; Hui RL; Chan J
Pharmacotherapy; 2012 Nov; 32(11):981-7. PubMed ID: 23074134
[TBL] [Abstract][Full Text] [Related]
5. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
[TBL] [Abstract][Full Text] [Related]
6. The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function.
Momper JD; Ridenour TA; Schonder KS; Shapiro R; Humar A; Venkataramanan R
Am J Transplant; 2011 Sep; 11(9):1861-7. PubMed ID: 21714845
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients.
Lichvar A; Tremblay S; Naik D; Lipscomb J; King E; Vinks AA; Christians U; Alloway RR
Pharmacotherapy; 2019 May; 39(5):564-575. PubMed ID: 30892704
[TBL] [Abstract][Full Text] [Related]
8. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study.
Melo MJ; Gonçalves J; Guerra JO; Santana A; Nascimento C
Transplant Proc; 2015 May; 47(4):911-3. PubMed ID: 26036484
[TBL] [Abstract][Full Text] [Related]
9. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
Staatz CE; Tett SE
Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
[TBL] [Abstract][Full Text] [Related]
10. EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus® versus Advagraf™ in liver transplant recipients.
Wöhl DS; James B; Götz M; Brennfleck F; Holub-Hayles I; Mutzbauer I; Baccar S; Brunner SM; Geissler EK; Schlitt HJ;
Trials; 2023 May; 24(1):325. PubMed ID: 37170284
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
[TBL] [Abstract][Full Text] [Related]
12. Systematic conversion to generic tacrolimus in stable kidney transplant recipients.
Rosenborg S; Nordström A; Almquist T; Wennberg L; Bárány P
Clin Kidney J; 2014 Apr; 7(2):151-155. PubMed ID: 24944783
[TBL] [Abstract][Full Text] [Related]
13. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients.
Alloway RR; Sadaka B; Trofe-Clark J; Wiland A; Bloom RD
Am J Transplant; 2012 Oct; 12(10):2825-31. PubMed ID: 22759200
[TBL] [Abstract][Full Text] [Related]
14. Converting immunosuppression from an oral suspension to a granule formulation of tacrolimus in pediatric renal transplant recipients.
Malakasioti G; Booth C; Marks SD
Pediatr Transplant; 2018 Aug; 22(5):e13214. PubMed ID: 29767471
[TBL] [Abstract][Full Text] [Related]
15. Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment.
Ma MK; Kwan LP; Mok MM; Yap DY; Tang CS; Chan TM
Ren Fail; 2013 Aug; 35(7):942-5. PubMed ID: 23815459
[TBL] [Abstract][Full Text] [Related]
16. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
Wakasugi N; Uchida H; Uno S
Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
[TBL] [Abstract][Full Text] [Related]
17. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients.
Wu MJ; Cheng CY; Chen CH; Wu WP; Cheng CH; Yu DM; Chuang YW; Shu KH
Transplantation; 2011 Sep; 92(6):648-52. PubMed ID: 21912349
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus-related adverse effects in liver transplant recipients: its association with trough concentrations.
Varghese J; Reddy MS; Venugopal K; Perumalla R; Narasimhan G; Arikichenin O; Shanmugam V; Shanmugam N; Srinivasan V; Jayanthi V; Rela M
Indian J Gastroenterol; 2014 May; 33(3):219-25. PubMed ID: 24740447
[TBL] [Abstract][Full Text] [Related]
19. Safety and Effectiveness of Conversion From Cyclosporine to Once-Daily Prolonged-Release Tacrolimus in Stable Kidney Transplant Patients: A Multicenter Observational Study in Japan.
Usuki S; Uno S; Sugamori H; Tanaka H; Aikawa A
Transplant Proc; 2018 Dec; 50(10):3266-3274. PubMed ID: 30577196
[TBL] [Abstract][Full Text] [Related]
20. The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients.
Sukkha S; Chindavijak B; Nosoongnoen W; Phakdeekitchareon B; Kitiyakara C; Sumethkul V
Drug Metab Pharmacokinet; 2020 Feb; 35(1):139-144. PubMed ID: 31727575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
